Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis
The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the exp...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2022-09, Vol.101 (39), p.e30815-e30815 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e30815 |
|---|---|
| container_issue | 39 |
| container_start_page | e30815 |
| container_title | Medicine (Baltimore) |
| container_volume | 101 |
| creator | Li, Dailong Li, Wanqiang Tian, Cheng Pang, Yaqi Xu, Lu Wang, Yuke Xu, Xinhua |
| description | The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC.
Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark).
Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42-0.70, P |
| doi_str_mv | 10.1097/MD.0000000000030815 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9524916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36181032</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4500-85fc730c36f2545615660f663a00d6473ca270439a41eef266e3bafeb9880d523</originalsourceid><addsrcrecordid>eNpdkdtOGzEQhq0KVA7tE1RCfoFNx8fd5QIpClAqgehFe205jr1x8dqRvSHw9ixJocBczPzSzP-NNIPQNwITAm39_eZ8Av-DQUPEJ3RIBJOVaCXfe6MP0FEpfwEIqyn_jA6YJA0BRg_R8CunLqYyeIN1XGATfPQmrfSwTCF13uiAi--id6OMxuLkcOwpq64Itg-rbEvxKWIfcUyxKr0OARs7prCOHd5a8ime4t4OutJRh8fiyxe073Qo9uu_eoz-XF78nl1V17c_fs6m15XhAqBqhDM1A8Oko4ILSYSU4KRkGmAhec2MpjVw1mpOrHVUSsvm2tl52zSwEJQdo7Mdd7We93ZhbByyDmqVfa_zo0raq_ed6JeqS_eqFZS3RI4AtgOYnErJ1r16CajnJ6ibc_XxCaPr5O3aV8_L1ccBvhvYpDDYXO7CemOzWlodhuWWJ-qWVhQohZaNl9ii2RPlXZM3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Li, Dailong ; Li, Wanqiang ; Tian, Cheng ; Pang, Yaqi ; Xu, Lu ; Wang, Yuke ; Xu, Xinhua</creator><creatorcontrib>Li, Dailong ; Li, Wanqiang ; Tian, Cheng ; Pang, Yaqi ; Xu, Lu ; Wang, Yuke ; Xu, Xinhua</creatorcontrib><description>The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC.
Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark).
Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42-0.70, P < .00001), TNM stage (OR = 1.70, 95% CI: 1.23-2.34, P = .001), and lymph node status (OR = 0.26, 95% CI, 0.17-0.39, P < .00001), but have no associate with sex, age, pathological type, and T stages. Additionally, low nm23-H1 expression reduced the 3-year survival rate (OR = 2.74, 95% CI: 1.54-4.86, P = .0006) and 5-year survival rate (OR = 2.78, 95% CI: 1.36-5.69, P = .005).
Nm23-H1 can be used as a biomarker to predict tumor invasiveness and evaluate the prognosis of patients with NSCLC.</description><identifier>ISSN: 1536-5964</identifier><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000030815</identifier><identifier>PMID: 36181032</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Biomarkers, Tumor - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Humans ; Lung Neoplasms - pathology ; Neoplasm Staging ; NM23 Nucleoside Diphosphate Kinases - metabolism ; Prognosis ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2022-09, Vol.101 (39), p.e30815-e30815</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4500-85fc730c36f2545615660f663a00d6473ca270439a41eef266e3bafeb9880d523</citedby><cites>FETCH-LOGICAL-c4500-85fc730c36f2545615660f663a00d6473ca270439a41eef266e3bafeb9880d523</cites><orcidid>0000-0002-0644-4791</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524916/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524916/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36181032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Dailong</creatorcontrib><creatorcontrib>Li, Wanqiang</creatorcontrib><creatorcontrib>Tian, Cheng</creatorcontrib><creatorcontrib>Pang, Yaqi</creatorcontrib><creatorcontrib>Xu, Lu</creatorcontrib><creatorcontrib>Wang, Yuke</creatorcontrib><creatorcontrib>Xu, Xinhua</creatorcontrib><title>Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC.
Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark).
Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42-0.70, P < .00001), TNM stage (OR = 1.70, 95% CI: 1.23-2.34, P = .001), and lymph node status (OR = 0.26, 95% CI, 0.17-0.39, P < .00001), but have no associate with sex, age, pathological type, and T stages. Additionally, low nm23-H1 expression reduced the 3-year survival rate (OR = 2.74, 95% CI: 1.54-4.86, P = .0006) and 5-year survival rate (OR = 2.78, 95% CI: 1.36-5.69, P = .005).
Nm23-H1 can be used as a biomarker to predict tumor invasiveness and evaluate the prognosis of patients with NSCLC.</description><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Neoplasm Staging</subject><subject>NM23 Nucleoside Diphosphate Kinases - metabolism</subject><subject>Prognosis</subject><subject>Systematic Review and Meta-Analysis</subject><issn>1536-5964</issn><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkdtOGzEQhq0KVA7tE1RCfoFNx8fd5QIpClAqgehFe205jr1x8dqRvSHw9ixJocBczPzSzP-NNIPQNwITAm39_eZ8Av-DQUPEJ3RIBJOVaCXfe6MP0FEpfwEIqyn_jA6YJA0BRg_R8CunLqYyeIN1XGATfPQmrfSwTCF13uiAi--id6OMxuLkcOwpq64Itg-rbEvxKWIfcUyxKr0OARs7prCOHd5a8ime4t4OutJRh8fiyxe073Qo9uu_eoz-XF78nl1V17c_fs6m15XhAqBqhDM1A8Oko4ILSYSU4KRkGmAhec2MpjVw1mpOrHVUSsvm2tl52zSwEJQdo7Mdd7We93ZhbByyDmqVfa_zo0raq_ed6JeqS_eqFZS3RI4AtgOYnErJ1r16CajnJ6ibc_XxCaPr5O3aV8_L1ccBvhvYpDDYXO7CemOzWlodhuWWJ-qWVhQohZaNl9ii2RPlXZM3</recordid><startdate>20220930</startdate><enddate>20220930</enddate><creator>Li, Dailong</creator><creator>Li, Wanqiang</creator><creator>Tian, Cheng</creator><creator>Pang, Yaqi</creator><creator>Xu, Lu</creator><creator>Wang, Yuke</creator><creator>Xu, Xinhua</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0644-4791</orcidid></search><sort><creationdate>20220930</creationdate><title>Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis</title><author>Li, Dailong ; Li, Wanqiang ; Tian, Cheng ; Pang, Yaqi ; Xu, Lu ; Wang, Yuke ; Xu, Xinhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4500-85fc730c36f2545615660f663a00d6473ca270439a41eef266e3bafeb9880d523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Neoplasm Staging</topic><topic>NM23 Nucleoside Diphosphate Kinases - metabolism</topic><topic>Prognosis</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Dailong</creatorcontrib><creatorcontrib>Li, Wanqiang</creatorcontrib><creatorcontrib>Tian, Cheng</creatorcontrib><creatorcontrib>Pang, Yaqi</creatorcontrib><creatorcontrib>Xu, Lu</creatorcontrib><creatorcontrib>Wang, Yuke</creatorcontrib><creatorcontrib>Xu, Xinhua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Dailong</au><au>Li, Wanqiang</au><au>Tian, Cheng</au><au>Pang, Yaqi</au><au>Xu, Lu</au><au>Wang, Yuke</au><au>Xu, Xinhua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2022-09-30</date><risdate>2022</risdate><volume>101</volume><issue>39</issue><spage>e30815</spage><epage>e30815</epage><pages>e30815-e30815</pages><issn>1536-5964</issn><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC.
Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark).
Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42-0.70, P < .00001), TNM stage (OR = 1.70, 95% CI: 1.23-2.34, P = .001), and lymph node status (OR = 0.26, 95% CI, 0.17-0.39, P < .00001), but have no associate with sex, age, pathological type, and T stages. Additionally, low nm23-H1 expression reduced the 3-year survival rate (OR = 2.74, 95% CI: 1.54-4.86, P = .0006) and 5-year survival rate (OR = 2.78, 95% CI: 1.36-5.69, P = .005).
Nm23-H1 can be used as a biomarker to predict tumor invasiveness and evaluate the prognosis of patients with NSCLC.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>36181032</pmid><doi>10.1097/MD.0000000000030815</doi><orcidid>https://orcid.org/0000-0002-0644-4791</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-5964 |
| ispartof | Medicine (Baltimore), 2022-09, Vol.101 (39), p.e30815-e30815 |
| issn | 1536-5964 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9524916 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Biomarkers, Tumor - metabolism Carcinoma, Non-Small-Cell Lung - pathology Humans Lung Neoplasms - pathology Neoplasm Staging NM23 Nucleoside Diphosphate Kinases - metabolism Prognosis Systematic Review and Meta-Analysis |
| title | Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A05%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20and%20clinicopathological%20significance%20of%20nm23-H1%20expression%20in%20non-small%20cell%20lung%20cancer:%20A%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Li,%20Dailong&rft.date=2022-09-30&rft.volume=101&rft.issue=39&rft.spage=e30815&rft.epage=e30815&rft.pages=e30815-e30815&rft.issn=1536-5964&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000030815&rft_dat=%3Cpubmed_cross%3E36181032%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36181032&rfr_iscdi=true |